NCT00593060 2023-05-24
Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer
Massachusetts General Hospital
Phase 1 Completed
Clinical Trials
10 trialsNCT01687673 2020-12-07
Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
University of California, San Francisco
Phase 2 Completed
NCT01008917 2019-05-09
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
University of California, San Francisco
Phase 1 Completed
NCT02423954 2018-07-02
NivoPlus
Western Regional Medical Center
Phase 1/2 Terminated
NCT01335074 2016-11-15
Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Philipps University Marburg
Phase 1/2 Withdrawn
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01079767 2014-03-04
Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT01281943 2013-07-04
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Washington University School of Medicine
Phase 2 Withdrawn
NCT01567930 2012-12-17
Temsirolimus as Second-line Therapy in HCC
University of Tennessee Cancer Institute
Phase 2 Unknown
NCT00593008 2011-12-02
Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Terminated